ESMO Open最新文献

{"title":"90P Clinical phenotyping of lung cancer-associated cachexia in relation to tumour volume in TRACERx","authors":"K. Koh , W.K. Liu , O. Al-Sawaf , C. Richard , K. Haase , R. Scott , S. Veeriah , C. Lombardelli , I. Furlani , J. Macrae , C. Swanton , M. Jamal-Hanjani","doi":"10.1016/j.esmoop.2024.103831","DOIUrl":"10.1016/j.esmoop.2024.103831","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103831"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"92P Prognostic value of tumor location and site-specific metastases in advanced biliary tract cancer","authors":"V.D.C. Patel, T. Barroso, C.A.L.D.B. Monteiro, J. Araújo, M. Dias, L. Goncalves, C.M.D.M.A. Moreira, G. Nogueira Da Costa, C.D. Abreu, L.A. Marques Da Costa","doi":"10.1016/j.esmoop.2024.103923","DOIUrl":"10.1016/j.esmoop.2024.103923","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103923"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"76P Immune engager compounds screening using CRC patient-derived organoids","authors":"C.M.A. Pinna , K. Rakhimova , J. Zhang , L. Tee , L. Bills , D. Millar , C. Blanc , N. Lal , E. Rottoli , H. Oisin , M. Gaspar , R. Lara , S. Cemerski , S.J. Dovedi , A.D. Beggs","doi":"10.1016/j.esmoop.2024.103817","DOIUrl":"10.1016/j.esmoop.2024.103817","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103817"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"97P Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)","authors":"P.T.M. Cheng , K. Schrader , C. Cremin , E. Cheung , A. Fisic , J. Topham , J. Karasinska , B. Chow , D. Schaeffer , D.J. Renouf","doi":"10.1016/j.esmoop.2024.103837","DOIUrl":"10.1016/j.esmoop.2024.103837","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103837"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ESMO Society Profile","authors":"","doi":"10.1016/S2059-7029(24)01722-8","DOIUrl":"10.1016/S2059-7029(24)01722-8","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103952"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology","authors":"K.H.J. Lim ,&nbsp;K. Kamposioras ,&nbsp;E. Élez ,&nbsp;J.B.A.G. Haanen ,&nbsp;C. Hardy ,&nbsp;K. Murali ,&nbsp;M. O’Connor ,&nbsp;C. Oing ,&nbsp;K. Punie ,&nbsp;E. de Azambuja ,&nbsp;J.Y. Blay ,&nbsp;S. Banerjee ,&nbsp;ESMO Resilience Task Force","doi":"10.1016/j.esmoop.2024.103634","DOIUrl":"10.1016/j.esmoop.2024.103634","url":null,"abstract":"<div><h3>Background</h3><div>Burnout in health care professionals (HCPs) results from exposure to psychosocial risks at work. Left unaddressed, burnout can lead to chronic health problems, increased staff turnover, reduced work hours, absenteeism, and early retirement from clinical practice, thus impacting patient care. The European Society for Medical Oncology (ESMO) Resilience Task Force (RTF) was established in December 2019 to support the well-being of oncology HCPs globally. This ESMO RTF position paper aims to provide a set of recommendations to optimise well-being and mitigate burnout in oncology, and to help individuals and institutions maintain the delivery of optimal cancer care.</div></div><div><h3>Design</h3><div>Recommendations were developed by a diverse multinational panel of interprofessional experts based on the key findings from three previously reported ESMO RTF surveys.</div></div><div><h3>Results</h3><div>Several recurrent work-related psychosocial risks in oncology were identified; in particular, concerns about workload and professional development. The need for flexible work patterns, continued use of virtual resources, well-being resources, and targeted support for at-risk groups were highlighted as key considerations to safeguard HCPs’ health and prevent burnout. In total, 11 recommendations relating to three priority themes were developed: (i) information and training; (ii) resources; (iii) activism and advocacy.</div></div><div><h3>Conclusion</h3><div>Optimising the well-being of oncology HCPs is essential for the provision of high-quality, sustainable care for patients globally. The ESMO RTF will continue its mission and is rolling out several initiatives and activities to support the implementation of these recommendations.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103634"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study","authors":"Á. Guerrero-Zotano ,&nbsp;J.M. Pérez-García ,&nbsp;M. Ruiz-Borrego ,&nbsp;B. Bermejo ,&nbsp;M. Gil-Gil ,&nbsp;J. de la Haba ,&nbsp;E. Alba Conejo ,&nbsp;V. Quiroga ,&nbsp;V. Carañana ,&nbsp;A. Urruticoechea ,&nbsp;S. Morales ,&nbsp;M. Bellet ,&nbsp;A. Antón ,&nbsp;M. Fernández-Abad ,&nbsp;P. Sánchez-Rovira ,&nbsp;L. Calabuig ,&nbsp;J. Pérez-Escuredo ,&nbsp;M. Sampayo-Cordero ,&nbsp;J. Cortés ,&nbsp;A. Llombart-Cussac","doi":"10.1016/j.esmoop.2024.103733","DOIUrl":"10.1016/j.esmoop.2024.103733","url":null,"abstract":"<div><h3>Background</h3><div>The effect of the addition of cyclin-dependent kinases 4 and 6 inhibitors to endocrine therapy in terms of molecular downstaging remains undetermined. Switching from a high-risk to a low risk Recurrence Score (RS) group could provide useful information to identify patients who might not require chemotherapy. The purpose of this study was to assess the biological and clinical activity of letrozole plus palbociclib as neoadjuvant treatment for patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with an initial Oncotype DX RS ≥18.</div></div><div><h3>Patients and methods</h3><div>Participants were women aged ≥18 years with HR-positive/HER2-negative, Ki67 ≥ 20%, stage II-IIIB early breast cancer with a baseline RS ≥18. Eligible patients with a pretreatment RS 18-25 (cohort A) and 26-100 (cohort B) received six 28-day cycles of letrozole (2.5 mg per day; plus goserelin if pre- or perimenopausal) plus palbociclib (125 mg per day; 3/1 schedule) before surgery. The primary endpoint for both cohorts was the proportion of patients who achieved an RS ≤25 at surgery or a pathological complete response (pCR).</div></div><div><h3>Results</h3><div>A total of 67 patients were enrolled, among which 65 were assessable for the primary endpoint (32 patients in cohort A and 33 in cohort B). At surgery, 22 (68.8%) patients in cohort A and 18 (54.5%) patients in cohort B had an RS ≤25 or a pCR [only 1 (3.0%) patient in cohort B], meeting the primary endpoint in cohort B (<em>P</em> &lt; 0.01), but not in cohort A (<em>P</em> = 0.98). No new safety signals were identified.</div></div><div><h3>Conclusions</h3><div>The efficacy of neoadjuvant treatment with letrozole plus palbociclib does not seem to depend on pretreatment RS for patients with RS ≥18. However, around half of patients with HR-positive/HER2-negative early breast cancer with an RS 26-100 at baseline achieved molecular downstaging with this regimen.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103733"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study","authors":"F. Tosi ,&nbsp;L. Salvatore ,&nbsp;E. Tamburini ,&nbsp;S. Artale ,&nbsp;S. Lonardi ,&nbsp;S. Marchetti ,&nbsp;A. Pastorino ,&nbsp;F. Pietrantonio ,&nbsp;A. Puccini ,&nbsp;F.L. Rojas-Llimpe ,&nbsp;B. Vincenzi ,&nbsp;S. Mariano ,&nbsp;F. Negri ,&nbsp;K. Bencardino ,&nbsp;C. Pinto ,&nbsp;C. Aschele ,&nbsp;S. Siena","doi":"10.1016/j.esmoop.2024.103929","DOIUrl":"10.1016/j.esmoop.2024.103929","url":null,"abstract":"<div><h3>Background</h3><div>Sustained clinical complete remissions were reported in all of 23 mismatch repair deficient/microsatellite instable (dMMR/MSI) locally advanced rectal cancer (LARC) patients treated with dostarlimab alone in a recent phase II study. These results led to off-label use of dostarlimab or other immune checkpoint inhibitors (ICIs) in dMMR/MSI-LARC even before regulatory approval. The present study [STAR(t)-IT-REDUCE] describes the outcome of dMMR/MSI-LARC patients treated with ICI in Italy.</div></div><div><h3>Materials and methods</h3><div>Investigator-initiated, observational, retrospective-cohort, multicentric study of ICI treatment in dMMR/MSI-LARC. Patients were eligible if treated with ≥1 ICI dose from July 2022 to December 2023 (date of approval of dostarlimab for this indication in Italy).</div></div><div><h3>Results</h3><div>Seventeen dMMR/MSI-LARC patients (13 of 17 treatment-naïve) were eligible. Fourteen patients completed 6 months of treatment, two discontinued after four doses and one after five doses because of immune-related pneumonia, social constraints, or non-oncological bowel obstruction, respectively. Overall, 16 of 17 assessable patients [94.1%; 95% confidence interval (CI) 69.24% to 99.69%, ‘ITT analysis’] achieved complete clinical response (cCR). Ten of 11 treatment-naïve patients completing 6 months of treatment had cCR (90.9%; 95% CI 57.12% to 99.52%, ‘per-protocol analysis’). One patient with near-CR underwent rectal surgery and minimal residual intramucosal tumor was found. With a median follow-up of 9.5 months, no local relapse occurred. One patient developed unconfirmed lung metastases. Two grade 3 and no grade 4 adverse events were reported.</div></div><div><h3>Conclusion</h3><div>The present STAR(t)-IT-REDUCE study documents the immunoablative and curative activity of ICI monotherapy in dMMR/MSI-LARC. Toxicity and compliance issues inherent to real-world practice are limited and do not affect achievement of initial complete tumor response but may limit response duration.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103929"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3O Pre-clinical pan-cancer drug repurposing via deep learning","authors":"B.A. Ocasio ,&nbsp;J. Hu ,&nbsp;V. Stathias ,&nbsp;M.J. Martinez ,&nbsp;K.L. Burnstein ,&nbsp;S.C. Schurer","doi":"10.1016/j.esmoop.2024.103749","DOIUrl":"10.1016/j.esmoop.2024.103749","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103749"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"31P Adult granulosa cell tumours of ovary: Analysis of 227 non-recurrent and recurrent cases","authors":"J. Hojný ,&nbsp;R. Michálková ,&nbsp;N. Hajkova ,&nbsp;E. Krkavcova ,&nbsp;P. Dundr ,&nbsp;K. Nemejcova","doi":"10.1016/j.esmoop.2024.103777","DOIUrl":"10.1016/j.esmoop.2024.103777","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103777"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}